

DSM International B.V.  
Form 4  
November 21, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
DSM International B.V.

2. Issuer Name **and** Ticker or Trading  
Symbol  
AMYRIS, INC. [AMRS]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)  
  
HET OVERLOON 1  
  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/19/2018

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting  
Person

HEERLEN, P7 6411 TE

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/19/2018		A		1,643,991	A	<u>11</u>	10,328,951	I	See footnote (2)
Common Stock	11/19/2018		X		964,837	A	\$ 0.0015	11,293,788	I	See footnote (2)
Common Stock	11/19/2018		X		1,713,565	A	\$ 0.0001	13,007,353	I	See footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.



**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying (Instr. 3 and 4)		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title
Warrants (right to buy)	\$ 0.0015	11/19/2018		J <sup>(3)</sup>		964,837		11/19/2018	07/10/2022	Common Stock
Warrants (right to buy)	\$ 0.0001	11/19/2018		J <sup>(4)</sup>		1,713,565		11/19/2018	05/23/2023	Common Stock
Warrants (right to buy)	\$ 0.0015	11/19/2018		X		964,837		11/19/2018	07/10/2022	Common Stock
Warrants (right to buy)	\$ 0.0001	11/19/2018		X		1,713,565		11/19/2018	05/23/2023	Common Stock

## Reporting Owners

Reporting Owner Name / Address	Relationships
	Director   10% Owner   Officer   Other

DSM International B.V.  
HET OVERLOON 1  
HEERLEN, P7 6411 TE

Koninklijke DSM N.V.  
HET OVERLOON 1  
HEERLEN, P7 6411 TE

## Signatures

DSM International B.V. By: /s/ Hugh Welsh, President, DSM North America

11/21/2018

                    Signature of Reporting Person

Date

Koninklijke DSM N.V. By: /s/ Hugh Welsh, President, DSM North America

11/21/2018



\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) In consideration of certain agreements of affiliates of the Reporting Persons set forth in a commercial agreement entered into with the Issuer on November 19, 2018, the Issuer's board of directors approved the issuance of the shares reported herein.  
  
The securities reported herein are held of record by DSM International B.V., which is a wholly owned subsidiary of Koninklijke DSM N.V. Accordingly, Koninklijke DSM N.V. may be deemed to share beneficial ownership of the securities held of record by DSM International B.V. Koninklijke DSM N.V. is a publicly traded company with securities listed on the Amsterdam Stock Exchange.
- (2) In connection with an investment in the Issuer by a third party on August 3, 2017, as agreed by DSM International B.V. and the Issuer on November 19, 2018, the anti-dilution provisions of the Warrants were triggered, resulting in the Warrants becoming exercisable for 964,837 shares of Common Stock at an exercise price of \$0.0015 per share, which Warrants were exercised by the Reporting Persons on November 19, 2018.
- (3) In connection with amendments to existing securities of the Issuer held by a third party on August 17, 2018, as agreed by DSM International B.V. and the Issuer on November 19, 2018, the anti-dilution provisions of the Warrants were triggered, resulting in the Warrants becoming exercisable for 1,713,565 shares of Common Stock at an exercise price of \$0.0001 per share, which Warrants were exercised by the Reporting Persons on November 19, 2018.
- (4)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.